Design, synthesis and biological activity of a pyrrolo [2, 1- c][1,4]benzodiazepine (PBD)-distamycin hybrid

Bioorganic and Medicinal Chemistry Letters

Volumn 8, Issue 21, 1998, Pages 3019-3024

  Baraldi, Pier Giovanni ^a   Cacciari, Barbara ^a   Guiotto, Andrea ^a   Leoni, Alberto ^a   Romagnoli, Romeo ^a   Spalluto, Giampiero ^a   Mongelli, Nicola ^b   Howard, Philip W ^c   Thurston, David E ^c   Bianchi, Nicoletta ^a   Gambari, Roberto ^a  

^a UNIVERSITY OF FERRARA   (Italy)

^b Preclinical Research Division   (Italy)

^c UNIVERSITY OF PORTSMOUTH   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ANTHRAMYCIN; ANTINEOPLASTIC ANTIBIOTIC; DISTAMYCIN A; NATURAL PRODUCT; PYRROLO[2,1 C][1,4]BENZODIAZEPINE DERIVATIVE;

ANTINEOPLASTIC ACTIVITY; ARTICLE; CELL GROWTH; DNA BINDING; DRUG ISOLATION; DRUG STRUCTURE; DRUG SYNTHESIS; GROWTH INHIBITION; HUMAN; HUMAN CELL; HYBRID; LEUKEMIA CELL; POLYMERASE CHAIN REACTION; STREPTOMYCES;

ANTINEOPLASTIC AGENTS; BENZODIAZEPINES; DISTAMYCINS; DNA; DRUG DESIGN; HUMANS; K562 CELLS; POLYMERASE CHAIN REACTION;

STREPTOMYCES;

EID: 17144446545     PISSN: 0960894X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0960-894X(98)00544-7     Document Type: Article

References (26)

1. 1. Zunino, F.; Animati, F.; Capranico, G. Current Pharmaceutical Design, 1995, 1, 83.
2. 2. Di Marco, A.; Gaetani, M.; Orezzi, P.; Scotti, T.; Arcamone, F. Cancer Chemother. Rep., 1962, 18, 5.
3. 3. Arcamone, F.; Orezzi, P.G.; Barbieri, W.; Nicolella, V.; Penco, S. Gazz. Chim. Ital., 1967, 97, 1097.
4. 4. Thurston, D.E.; Bose, D.S. Chem. Rev., 1994, 94, 433.
5. 5. Leimgruber, W.; Batcho, A.D.; Czajkowski, R.C. J. Am. Chem. Soc., 1968, 90, 5641.
6. 6. Kopka, M.L.; Goodsell, D.S.; Baikalov, I.; Grzeskowiak, K.; Cascio, D.; Dickerson, R.E. Biochem., 1994, 33, 13593.
7. 7. Guiotto, A.; Howard, P.W.; Baraldi, P.G.; Thurston, D.E. Bioorg. Med. Chem. Lett., 1998 (In press)
8. 8. Windholz, T.B.; Johnston, D.B.R. Tetrahedron Lett., 1967, 27, 2555.
9. 9. Dong, Q.; Andreson, C.E.; Ciufolini, M.A. Tetrahedron Lett., 1995, 36, 5681.
10. 10. Arcamone, F.; Nicolella, V.; Penco, S.; Redaelli, S. Gazzetta Chim. Ital., 1969, 99, 632.
11. 6) δ: 1.9 (m, 4H); 2.6 (t, J= 6.4 Hz, 2H); 2.78 (m, 2H); 3.4 (m, 4H); 3.73 (s, 3H); 3.77 (s, 3H); 3.80 (s, 3H); 3.84 (s, 3H); 4.3 (m, 2H); 5.7 (s, 1H); 6.9-7.3 (m, 8H); 8.2 (t, J = 7.3 Hz, 2H); 8.68 (s, 2H); 9.01 (s, 2H); 9.94 (s, 1H); 9.95 (s, 1H); 10.1 (s, 1H). Elemental analysis (calcd): C 56.23; H 5.61; N 19.5; Cl 4.49; (found): C 55.99; H 5.53; N 19.7; Cl 4.31. Mass (Maldi-Tof): 756 (M+2).
12. 12. Lozzio, C.B.; Lozzio, B.B. Blood, 1975, 45 , 321.
13. 13. Passadore, M.; Bianchi, N.; Feriotto, G.; Mischiati, C.; Giacomini, P.; Piva, R.; Gambari, R. Biochem. J., 1995, 308, 513
14. 14. Piva, R.; Gambari, R.; Zorzato, F.; Kumar, L.; del Senno, L. Biochem Biophys Res Commun 1992, 183, 996.
15. 15. Santos, E.; Tronick, S.R.; Aaranson, S.A.; Pulciani, S.; Barbacid, M. Nature , 1982, 298, 343.
16. 16. Piva, R.; del Senno, L. Ann NY Acad Sci USA , 1993, 68, 235.
17. 17. del Senno, L.; Aguiari, G.L.; Piva, R. Human Molec. Genetics , 1992, 1, 354.
18. 18. Bianchi, N.; Passadore, M.; Feriotto, G.; Mischiati, C.; Gambari, R.; Piva, R. J. Steroid Biochem. Molec . Biol., 1995, 54, 211.
19. 19. Bianchi, N.; Passadore, M.; Rutigliano, C.; Feriotto, G.; Mischiati, C.; Gambari, R. Biochem . Pharmacol ., 1996, 52, 1489.
20. 20. Passadore, M.; Bianchi, N.; Feriotto, G.; Mischiati, C.; Rutigliano, C.; Gambari, R. Eur. J. Pharmacol., 1997, 319, 317.
21. 50 was determined by comparing the cell number/ml of K562 cells treated with DNA-binding drugs to the value of untreated control cell cultures after 48h of continuos exposure to at least 4 concentrations of each drug.
22. 22. For the amplification of the 5′-region of the human oestrogen receptor gene, the target DNA was either the pBLCAT8ERCAT1 plasmid or human genomic DNA.
23. 23. The amplification primers for codon 61 regions of the Ha-ras oncogene were from the ras PointPrimers™ kit (Oncogene Sciences, Uniondale, NY, USA). For the amplification of the Ha-ras oncogene, the target DNA was human genomic DNA.
24. 24. The effects of DNA-binding drugs were analysed after incubating target DNA at room temperature, for 5 min, with increasing amounts of the compounds, as reported in the text, followed by polymerase chain reaction. Amplified DNA was analysed by electrophoresis on 2.5% agarose, in TAE (0.04 M Tris-acetate, 0.001 M EDTA), 0.5 μg/ml ethidium bromide. Conditions of Ha-ras PCR were: denaturation, 92 °C, 45 sec; annealing, 62 °C, 45 sec; elongation, 72 °C, 30 sec (32 cycles); conditions of oestrogen receptor PCR were: denaturation, 92 °C, 45 sec; annealing, 58 °C, 1 min; elongation, 72 °C, 1 min (32 cycles).
25. 25. Hurley, L.H. J. Antibiot. 1977, 30, 349.
26. 26. Lown, J.W.; Joshua, A.W. Biochem. Pharmacol. 1979, 28, 2017.